Trial Profile
Phase I single ascending dose trial of deuterium-modified ivacaftor for the treatment of cystic fibrosis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Deutivacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 28 Apr 2016 Results published in Concert Pharmaceuticals media release.
- 08 Oct 2015 Results published in a Concert Pharmaceuticals media release.
- 22 Sep 2015 The data from this trial will be presented in the poster session at the North American Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.